Aligos Therapeutics, Inc. (ALGS)
8.54
+0.54
(+6.75%)
USD |
NASDAQ |
Jan 22, 16:00
8.59
+0.05
(+0.59%)
Pre-Market: 20:00
Aligos Therapeutics EPS Diluted (Quarterly): -3.041 for Sept. 30, 2025
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Johnson & Johnson | 2.098 |
| CEL-SCI Corp. | -0.7611 |
| AIM ImmunoTech, Inc. | -1.567 |
| IGC Pharma, Inc. | -0.0201 |
| NovaBay Pharmaceuticals, Inc. | -0.22 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -31.54M |
| Revenue (Quarterly) | 0.741M |
| Total Expenses (Quarterly) | 32.28M |
| Enterprise Value | -40.59M |
| Gross Profit Margin (Quarterly) | 70.31% |
| Profit Margin (Quarterly) | -4.26K% |
| Earnings Yield | -231.4% |
| Normalized Earnings Yield | -227.12 |